Polymorphism of human cytochrome P450 enzymes and its clinical impact
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …
specific genes affect drug response. This article highlights current pharmacogenetic …
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Human cytochrome P450 enzymes
FP Guengerich - Cytochrome P450: structure, mechanism, and …, 2015 - Springer
Abstract The cytochrome P450 (P450) enzymes first attracted interest because of their
relevance to the metabolism of drugs, steroids, and carcinogens. Collectively, the 57 human …
relevance to the metabolism of drugs, steroids, and carcinogens. Collectively, the 57 human …
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
JA Goldstein - British journal of clinical pharmacology, 2001 - Wiley Online Library
The human CYP2Cs are an important subfamily of P450 enzymes that metabolize
approximately 20% of clinically used drugs. There are four members of the subfamily …
approximately 20% of clinically used drugs. There are four members of the subfamily …
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
Abstract Cytochrome P450 (CYP) 2C8 is the principal enzyme responsible for the
metabolism of the anti-cancer drug paclitaxel (Taxol). It is also the predominant P450 …
metabolism of the anti-cancer drug paclitaxel (Taxol). It is also the predominant P450 …
Population genetic structure of variable drug response
JF Wilson, ME Weale, AC Smith, F Gratrix, B Fletcher… - Nature …, 2001 - nature.com
Geographic patterns of genetic variation, including variation at drug metabolizing enzyme
(DME) loci and drug targets, indicate that geographic structuring of inter-individual variation …
(DME) loci and drug targets, indicate that geographic structuring of inter-individual variation …
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies
T Furuta, N Shirai, M Sugimoto, A Nakamura… - Drug metabolism and …, 2005 - jstage.jst.go.jp
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole,
esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There …
esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There …
Human cytochromes P450
JA Hasler, R Estabrook, M Murray, I Pikuleva… - Molecular aspects of …, 1999 - Elsevier
The cytochrome P450 proteins (CYPs) are a family of haem proteins resulting from
expression of a gene super-family that currently contains around 1000 members in species …
expression of a gene super-family that currently contains around 1000 members in species …
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19
SA Scott, K Sangkuhl, AR Shuldiner… - Pharmacogenetics …, 2012 - journals.lww.com
The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …